Tags

Type your tag names separated by a space and hit enter

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.
Am Heart J. 1982 Jul; 104(1):66-72.AH

Abstract

The efficacy, safety, and tolerance of pentoxifylline (Trental, Hoechst-Roussel Pharmaceuticals, Inc.) in the treatment of intermittent claudication associated with chronic occlusive arterial disease (COAD) were evaluated in a double-blind, placebo-controlled, parallel-group, multicenter clinical trial involving a total of 128 outpatients. The response to treatment was ascertained at regular intervals during the trial by measuring the distance walked prior to the onset of claudication when patients were subjected to a standardized treadmill test. Pentoxifylline given orally in doses up to 1200 mg/day was significantly more effective than placebo in increasing both the initial and absolute claudication distances in patients with COAD. Reduction of lower limb paresthesias also suggested greater clinical improvement in the pentoxifylline treated patients. These results support the hypothesis that pentoxifylline reduces blood viscosity by improving red cell flexibility, and thereby enhances blood flow in patients with COAD. White the precise mode of therapeutic action requires clarification, pentoxifylline was well tolerated with minimal unwanted effects.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

7046409

Citation

Porter, J M., et al. "Pentoxifylline Efficacy in the Treatment of Intermittent Claudication: Multicenter Controlled Double-blind Trial With Objective Assessment of Chronic Occlusive Arterial Disease Patients." American Heart Journal, vol. 104, no. 1, 1982, pp. 66-72.
Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104(1):66-72.
Porter, J. M., Cutler, B. S., Lee, B. Y., Reich, T., Reichle, F. A., Scogin, J. T., & Strandness, D. E. (1982). Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. American Heart Journal, 104(1), 66-72.
Porter JM, et al. Pentoxifylline Efficacy in the Treatment of Intermittent Claudication: Multicenter Controlled Double-blind Trial With Objective Assessment of Chronic Occlusive Arterial Disease Patients. Am Heart J. 1982;104(1):66-72. PubMed PMID: 7046409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. AU - Porter,J M, AU - Cutler,B S, AU - Lee,B Y, AU - Reich,T, AU - Reichle,F A, AU - Scogin,J T, AU - Strandness,D E, PY - 1982/7/1/pubmed PY - 1982/7/1/medline PY - 1982/7/1/entrez SP - 66 EP - 72 JF - American heart journal JO - Am. Heart J. VL - 104 IS - 1 N2 - The efficacy, safety, and tolerance of pentoxifylline (Trental, Hoechst-Roussel Pharmaceuticals, Inc.) in the treatment of intermittent claudication associated with chronic occlusive arterial disease (COAD) were evaluated in a double-blind, placebo-controlled, parallel-group, multicenter clinical trial involving a total of 128 outpatients. The response to treatment was ascertained at regular intervals during the trial by measuring the distance walked prior to the onset of claudication when patients were subjected to a standardized treadmill test. Pentoxifylline given orally in doses up to 1200 mg/day was significantly more effective than placebo in increasing both the initial and absolute claudication distances in patients with COAD. Reduction of lower limb paresthesias also suggested greater clinical improvement in the pentoxifylline treated patients. These results support the hypothesis that pentoxifylline reduces blood viscosity by improving red cell flexibility, and thereby enhances blood flow in patients with COAD. White the precise mode of therapeutic action requires clarification, pentoxifylline was well tolerated with minimal unwanted effects. SN - 0002-8703 UR - https://www.unboundmedicine.com/medline/citation/7046409/Pentoxifylline_efficacy_in_the_treatment_of_intermittent_claudication:_multicenter_controlled_double_blind_trial_with_objective_assessment_of_chronic_occlusive_arterial_disease_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-8703(82)90642-1 DB - PRIME DP - Unbound Medicine ER -